Skip to main content
SpringerLink
Log in

Temsirolimus in Relapsed and/or Refractory Mantle Cell Lymphoma

Profile Report

  • Adis Profile Report
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. The Leukemia and Lymphoma Society. Mantle cell lymphoma [online]. Available from URL: http://www.leukemia-lymphoma.org/attachments/National/br_1172589724.pdf[Accessed 2010 Apr 15]

  2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin’s lymphomas. 1.2010 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf[Accessed 2010 Aug 23]

  3. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009 Aug; 27 (23): 3822–9

    Article  PubMed  CAS  Google Scholar 

  4. Gill S, Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008 Mar; 49 (3): 398–409

    Article  PubMed  CAS  Google Scholar 

  5. Weigert O, Unterhalt M, Hiddemann W, et al. Current management of mantle cell lymphoma. Drugs 2007; 67 (12): 1689–702

    Article  PubMed  CAS  Google Scholar 

  6. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma 2009 Dec; 50 (12): 1916–30

    Article  PubMed  CAS  Google Scholar 

  7. Hess G, Smith SM, Berkenblit A, et al. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Oncol 2009 Dec; 36 Suppl. 3: S37–45

    Article  PubMed  CAS  Google Scholar 

  8. European Medicines Agency. Torisel: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000799/WC500039912.pdf[Accessed 2010 Jul 9]

  9. Hoy SM, McKeage K. Temsirolimus: in relapsed and/or refractory mantle cell lymphoma. Drugs 2010; 70 (14): 1819–29

    Article  PubMed  CAS  Google Scholar 

  10. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23 (23): 5347–56

    Article  PubMed  CAS  Google Scholar 

  11. European Medicines Agency. Torisel: assessment report [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000799/WC500039918.pdf[Accessed 2010 Apr 1]

  12. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005 Aug; 23 (23): 5314–22

    Article  PubMed  CAS  Google Scholar 

  13. Ansell SM, Inwards DJ, Rowland Jr KM, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008 Aug; 113 (3): 508–14

    Article  PubMed  CAS  Google Scholar 

  14. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 May; 356 (22): 2271–81

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments and Disclosures

The original article[9] from which this profile report was derived was reviewed by: G. Hess, Department of Haematology/Oncology, Johannes Gutenberg-University, Mainz, Germany; S.M. Smith, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois, USA.

The manufacturer of the agent under review was offered an opportunity to comment on the original article[9] during the peer review process; changes resulting from comments received were made on the basis of scientific and editorial merit. The preparation of the original article and this profile report was not supported by external funding.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Sheridan M. Hoy & Kate McKeage

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheridan M. Hoy.

Additional information

Adapted and reproduced from the original article published in Drugs 2010; 70 (14): 1819–29

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoy, S.M., McKeage, K. Temsirolimus in Relapsed and/or Refractory Mantle Cell Lymphoma. BioDrugs 25, 193–195 (2011). https://doi.org/10.2165/11207050-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11207050-000000000-00000

Keywords

Search

Navigation